Keywords: ImmunoGen, IMGN853, IMGN529, Ovarian cancer, IND, Ph I, Non-Hodgkin's lymphoma

ImmunoGen IND for IMGN853 now active; IMGN529 trial commenced

Article | 17 April 2012

Print This

US biotechnology firm ImmunoGen (Nasdaq: IMGN) says that the Investigational New Drug (IND) application for its IMGN853 product candidate is ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in